Recent news coverage includes earnings call transcripts of other companies and market commentary, with no direct recent news on Protagenic Therapeutics.

• Protagenic completed the multiple-dose portion of its Phase I study in healthy volunteers in December 2025 and plans to begin Phase II studies in late 2026 [S1].
• The company entered into and unwound a reverse merger with Phytanix Bio during the year ended March 31, 2026, affecting financial comparability [S1].
• Protagenic's common stock was delisted from Nasdaq effective January 5, 2026, and now trades on the OTCQB under the symbol PTIX, reducing liquidity [S1].
• Recent business news includes earnings call transcripts for other companies such as Harmonic, Usio, Kimball Electronics, and Stantec, but no direct news on Protagenic [N1][N5][N6][N8].

Protagenic's lead compound PT00114 addresses a large unmet need in stress-related neuropsychiatric disorders with a novel mechanism of action supported by preclinical efficacy. Clinical development progress could establish a differentiated therapeutic option for treatment-resistant depression, anxiety, PTSD, and substance use disorders. The company's exclusive intellectual property rights and ongoing pipeline development in the TCAP family could build a broad portfolio. Strategic partnerships and commercialization efforts could enhance market access and growth potential.

Protagenic faces significant risks including the inherent uncertainties of clinical trial outcomes, regulatory approval challenges, and the need for substantial additional financing. The company has no current revenues and limited cash runway, with operating losses continuing. Competition from larger, more established pharmaceutical companies with greater resources may limit market penetration. Manufacturing and supply chain dependencies on third parties and potential intellectual property disputes add operational risks. The company's stock is delisted from Nasdaq, reducing liquidity and investor access.

Protagenic's moat is based on its proprietary, patent-protected lead compound PT00114, a first-in-class synthetic peptide with a novel mechanism targeting stress-related neuropsychiatric disorders. The exclusive worldwide license from the University of Toronto and rights to additional intellectual property provide a protected position. The involvement of a leading clinical expert in psychiatric disorders supports clinical development credibility. However, the company faces competition from larger pharmaceutical firms with greater resources and experience. The early clinical stage and lack of commercial products limit current competitive advantages.

• Clinical Development Risk: The company is in early clinical stages with no approved products; failure or delays in clinical trials could adversely affect progress.
• Regulatory Approval Risk: Obtaining necessary approvals from FDA and other agencies is uncertain and may require additional costly studies.
• Financial Risk: Protagenic has incurred significant losses and has limited cash resources, requiring additional financing to continue operations.
• Competitive Risk: The company competes with larger pharmaceutical firms with greater resources and experience, which may impact market success.
• Intellectual Property Risk: Dependence on licensed patents and potential disputes or expiration could affect exclusivity and competitive position.
• Operational Risk: Reliance on third-party manufacturers and collaborators may cause delays or disruptions in development and commercialization.
• Market and Commercialization Risk: Lack of internal sales and marketing capabilities requires partnerships or development of infrastructure, which may be challenging.

• Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for stress-related neuropsychiatric and mood disorders [S1].
• The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide-1 (TCAP-1), an endogenous brain signaling peptide that dampens overactive stress responses [S1].
• PT00114 has demonstrated efficacy in preclinical animal models for depression, anxiety, substance abuse and addiction, and PTSD, working through a novel mechanism of action [S1].
• Protagenic holds exclusive worldwide rights to PT00114 through a license agreement with the University of Toronto and rights to additional intellectual property from Dr. David Lovejoy's laboratory [S1].
• The company is developing follow-on compounds in the TCAP family to build a pipeline of assets with differentiated features [S1].
• Preclinical work to begin clinical trials was completed in the first half of 2023; the first human trial started on September 26, 2023 [S1].
• The single-dose portion of the Phase I trial was completed with results announced on May 22, 2024; the multiple-dose portion was completed in December 2025 [S1].
• A Phase 2 study to evaluate PT00114 in a targeted population of patients with chronic stress-related psychiatric disorders was planned for late 2026 [S1].
• The clinical program is led by Dr. Maurizio Fava, a recognized expert in psychiatric disorders and principal investigator of the Phase I/IIa clinical study [S1].
• The Phase I/IIa study evaluates safety, tolerability, and early activity of PT00114 in healthy volunteers and patients with psychiatric illnesses, starting with Generalized Anxiety Disorder (GAD) patients [S1].
• Subsequent cohorts include patients with Major Depressive Disorder (MDD), Substance Use Disorder (SUD), and Post-Traumatic Stress Disorder (PTSD), all with suboptimal response or intolerance to existing treatments [S1].
• The company stratifies patients by corticosterone levels to identify those more likely to benefit, linking preclinical and clinical observations [S1].
• The market for stress-related neuropsychiatric disorders is large, with high unmet medical need and limited efficacy of current treatments [S1].
• Protagenic has no sales, marketing, or distribution capabilities currently and plans to either develop these internally or collaborate with third parties [S1].
• The company relies on third-party contract manufacturers for synthesis of PT00114 under cGMP conditions; the initial dosage form is a subcutaneous injection with other routes under development [S1].
• Protagenic entered into and subsequently unwound a reverse merger with Phytanix Bio during the year ended March 31, 2026, limiting comparability of financials [S1].
• As of June 30, 2026, the company had cash and equivalents of $191,674, current assets of $709,871, current liabilities of $1,072,614, resulting in a current ratio of 0.66 and cash ratio of 0.18 [S2].
• The company reported a net loss of $963,616 and basic and diluted EPS of -$0.53 for the quarter ended June 30, 2026 [S2].
• Protagenic has incurred significant operating losses since inception, with an accumulated deficit of $4,029,629 as of March 31, 2026, and expects to continue incurring losses [S1].
• The company has sufficient resources to fund operations until the end of the third quarter of 2026 based on cash resources as of March 31, 2026 [S1].
• The company’s common stock was delisted from Nasdaq effective January 5, 2026, and now trades on the OTCQB under the symbol PTIX, with reduced liquidity [S1].
• Protagenic has a Technology License Agreement with the University of Toronto, including royalty obligations of 2.5% of net sales and sublicensing fees [S1].
• The company faces risks including clinical trial execution, regulatory approvals, competition from larger pharmaceutical companies, intellectual property challenges, and the need for additional financing [S1].
• Recent business news coverage includes earnings call transcripts of other companies and market commentary but no direct recent news on Protagenic Therapeutics [N1][N5][N6][N7][N8].